- Home
- SRBK vs ATRA Comparison
SRBK vs ATRA Comparison
Compare SRBK & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$17.29
Company Overview
Basic Information| Metric | SRBK | ATRA |
|---|---|---|
| Founded | 1887 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.0M | 129.4M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | SRBK | ATRA |
|---|---|---|
| Price | $16.53 | $17.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 34.4K | ★ 71.0K |
| Earning Date | 01-30-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.21% | N/A |
| EPS Growth | ★ 374.69 | N/A |
| EPS | 0.54 | ★ 1.97 |
| Revenue | $31,130,000.00 | ★ $151,930,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $30.57 | ★ $8.94 |
| Revenue Growth | 0.85 | ★ 51.27 |
| 52 Week Low | $11.36 | $5.01 |
| 52 Week High | $17.11 | $18.71 |
Technical Indicators
Market Signals| Indicator | SRBK | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 66.92 | 62.98 |
| Support Level | $16.41 | $14.37 |
| Resistance Level | $17.11 | $18.25 |
| Average True Range (ATR) | 0.43 | 1.24 |
| MACD | 0.08 | 0.36 |
| Stochastic Oscillator | 70.97 | 81.80 |
Price Performance
Historical Comparison SRBK
ATRA
About SRBK SR Bancorp Inc.
SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).